BACKGROUND AND AIMS: The optimal type of stent for the palliation of malignant biliary obstruction in patients with pancreatic adenocarcinoma undergoingneoadjuvant chemoradiotherapy with curative intent is unknown. We performed a prospective trial comparing 3 types of biliary stents-fully covered self-expandable metal (fcSEMS), uncovered self-expandable metal (uSEMS), and plastic-to determine which best optimized cost-effectiveness and important clinical outcomes. METHODS: In this prospective randomized trial, consecutive patients with malignant biliary obstruction from newly diagnosed pancreatic adenocarcinoma who were to start neoadjuvant chemoradiotherapy were randomized to receive fcSEMSs, uSEMSs, or plastic stents during the index ERCP. The primary outcomes were time to stent occlusion, attempted surgical resection, or death after the initiation of neoadjuvant therapy, and the secondary outcomes were total patient costs associated with the stent, including the index ERCP cost, downstream hospitalization cost due to stent occlusion, and the cost associated with procedural adverse event. RESULTS:Fifty-four patients were randomized and reached the primary end point: 16 in the fcSEMS group, 17 in the uSEMS group, and 21 in the plastic stent group. No baseline demographic or tumor characteristic differences were noted among the groups. The fcSEMSs had a longer time to stent occlusion compared with uSEMSs and plastic stents (220 vs 74 and 76 days, P < .01), although the groups had equivalent rates of stent occlusion, attempted surgical resection, and death. Although SEMS placement cost more during the index ERCP (uSEMS = $24,874 and fcSEMS = $22,729 vs plastic = $18,701; P < .01), they resulted in higher procedural AE costs per patient (uSEMS = $5522 and fcSEMS = $12,701 vs plastic = $0; P < .01). Conversely, plastic stents resulted in an $11,458 hospitalization cost per patient due to stent occlusion compared with $2301 for uSEMSs and $0 for fcSEMSs (P < .01). CONCLUSIONS: In a prospective trial comparing fcSEMSs, uSEMSs, and plastic stents for malignant biliary obstruction in patients undergoing neoadjuvant therapy with curative intent for pancreatic adenocarcinoma, no stent type was superior in optimizing cost-effectiveness, although fcSEMSs resulted in fewer days of neoadjuvant treatment delay and a longer time to stent occlusion. (Clincial trial registration number: NCT01038713.).
RCT Entities:
BACKGROUND AND AIMS: The optimal type of stent for the palliation of malignant biliary obstruction in patients with pancreatic adenocarcinoma undergoing neoadjuvant chemoradiotherapy with curative intent is unknown. We performed a prospective trial comparing 3 types of biliary stents-fully covered self-expandable metal (fcSEMS), uncovered self-expandable metal (uSEMS), and plastic-to determine which best optimized cost-effectiveness and important clinical outcomes. METHODS: In this prospective randomized trial, consecutive patients with malignant biliary obstruction from newly diagnosed pancreatic adenocarcinoma who were to start neoadjuvant chemoradiotherapy were randomized to receive fcSEMSs, uSEMSs, or plastic stents during the index ERCP. The primary outcomes were time to stent occlusion, attempted surgical resection, or death after the initiation of neoadjuvant therapy, and the secondary outcomes were total patient costs associated with the stent, including the index ERCP cost, downstream hospitalization cost due to stent occlusion, and the cost associated with procedural adverse event. RESULTS: Fifty-four patients were randomized and reached the primary end point: 16 in the fcSEMS group, 17 in the uSEMS group, and 21 in the plastic stent group. No baseline demographic or tumor characteristic differences were noted among the groups. The fcSEMSs had a longer time to stent occlusion compared with uSEMSs and plastic stents (220 vs 74 and 76 days, P < .01), although the groups had equivalent rates of stent occlusion, attempted surgical resection, and death. Although SEMS placement cost more during the index ERCP (uSEMS = $24,874 and fcSEMS = $22,729 vs plastic = $18,701; P < .01), they resulted in higher procedural AE costs per patient (uSEMS = $5522 and fcSEMS = $12,701 vs plastic = $0; P < .01). Conversely, plastic stents resulted in an $11,458 hospitalization cost per patient due to stent occlusion compared with $2301 for uSEMSs and $0 for fcSEMSs (P < .01). CONCLUSIONS: In a prospective trial comparing fcSEMSs, uSEMSs, and plastic stents for malignant biliary obstruction in patients undergoing neoadjuvant therapy with curative intent for pancreatic adenocarcinoma, no stent type was superior in optimizing cost-effectiveness, although fcSEMSs resulted in fewer days of neoadjuvant treatment delay and a longer time to stent occlusion. (Clincial trial registration number: NCT01038713.).
Authors: Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan Journal: Ann Surg Oncol Date: 2009-04-24 Impact factor: 5.344
Authors: J Marc Pipas; Richard J Barth; Bassem Zaki; Michael J Tsapakos; Arief A Suriawinata; Michael A Bettmann; Justin M Cates; Gregory H Ripple; John E Sutton; Stuart R Gordon; Carol E McDonnell; Raymond P Perez; Nancy Redfield; Louise P Meyer; John F Marshall; Bernard F Cole; Thomas A Colacchio Journal: Ann Surg Oncol Date: 2005-11-01 Impact factor: 5.344
Authors: Patrick R Pfau; Douglas K Pleskow; Subhas Banerjee; Bradley A Barth; Yasser M Bhat; David J Desilets; Klaus T Gottlieb; John T Maple; Uzma D Siddiqui; Jeffrey L Tokar; Amy Wang; Louis-Michel Wong Kee Song; Sarah A Rodriguez Journal: Gastrointest Endosc Date: 2013-03 Impact factor: 9.427
Authors: J M Pipas; S E Mitchell; R J Barth; R Vera-Gimon; J Rathmann; L P Meyer; R S Wagman; L D Lewis; C McDonnell; T A Colacchio; R P Perez Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Daisy Walter; Petra G A van Boeckel; Marcel J Groenen; Bas L A M Weusten; Ben J Witteman; Gi Tan; Menno A Brink; Jan Nicolai; Adriaan C Tan; Joyce Alderliesten; Niels G Venneman; Wim Laleman; Jeroen M Jansen; Alexander Bodelier; Frank L Wolters; Laurens A van der Waaij; Ronald Breumelhof; Frank T M Peters; Robbert C H Scheffer; Max Leenders; Meike M C Hirdes; Ewout W Steyerberg; Frank P Vleggaar; Peter D Siersema Journal: Gastroenterology Date: 2015-03-17 Impact factor: 22.682
Authors: J M Pipas; B I Zaki; M M McGowan; M J Tsapakos; G H Ripple; A A Suriawinata; G J Tsongalis; T A Colacchio; S R Gordon; J E Sutton; A Srivastava; K D Smith; T B Gardner; M Korc; T H Davis; M Preis; S M Tarczewski; T A MacKenzie; R J Barth Journal: Ann Oncol Date: 2012-05-09 Impact factor: 32.976
Authors: Thiago F Nunes; Rômulo F T Santos; Tiago K Tibana; Thiago A Domingos; Edson Marchiori; Vinicius A V Fornazari; Joaquim Maurício da Motta-Leal-Filho; Denis Szejnfeld Journal: Abdom Radiol (NY) Date: 2020-06-30
Authors: Mohammad Bilal; Madhuri Chandnani; Nicholas M McDonald; Corey S Miller; James Saperia; Vaibhav Wadhwa; Shailendra Singh; Jonah M Cohen; Tyler M Berzin; Mandeep S Sawhney; Douglas K Pleskow Journal: Endosc Int Open Date: 2021-04-22